| Literature DB >> 35774978 |
Ting-Yu Cheng1, Magnus R Campler1, Declan C Schroeder2,3, My Yang2, Sunil K Mor2, Juliana B Ferreira4, Andréia G Arruda1.
Abstract
The detection and co-circulation of multiple variants of porcine reproductive and respiratory syndrome virus (PRRSV) have been observed and reported in swine. However, the potential long-term impact of multiple prevailing PRRSV variants on pig-performance is not yet fully understood. The primary objective of this study was to describe the genetic variation of PRRSV in processing fluid (PF), oral fluid (OF), and tonsil scraping (TS) specimens from five swine farms with different production types and PRRS status over a period of time (~1 year). Furthermore, the association between PRRSV prevalence and production parameters was investigated. Results showed that PRRSV was detected by RT-qPCR in 21-25% of all types of specimens. In breeding farms, PRRSV detection in PF and/or TS samples was correlated with stillborn and mummified fetuses, and pre-weaning mortality throughout the study period. Although ORF5 sequences were obtained in <16% of all sample types, simultaneous detection of PRRSV variants including field and vaccine strains within a single sampling event was identified in both breeding and growing pig farms. Phylogenetic analyses based on the ORF5 sequence classified the detected field PRRSV into L1A and L1H, two sub-lineages of lineage 1 (L1). Our study demonstrated the presence of multiple PRRSV lineages, sub-lineages, and variants in swine herds and its potential association with swine reproductive performance under field conditions.Entities:
Keywords: oral fluid; porcine reproductive and respiratory syndrome virus; processing fluid; swine; tonsil scrapings; viral lineage
Year: 2022 PMID: 35774978 PMCID: PMC9237545 DOI: 10.3389/fvets.2022.884733
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Lineages of Porcine reproductive and respiratory syndrome virus (PRRSV) open reading frame 5 (ORF5) sequences isolated overtime.
Sequences > 98% identical to L8 (Fostera® PRRS; Zoetis Inc.) and L5 (Ingelvac PRRS® MLV, Boehringer Ingelheim) vaccine strains.
Farm 1: Latest PRRSV outbreak ~6 months prior to the first sampling event; Farm 2: Latest PRRSV outbreak <1 month prior to the first sampling event and vaccinated with a modified live vaccine (Fostera® PRRS, Zoetis Inc); Farm 3: Vaccinated with a modified live vaccine (Ingelvac PRRS® MLV, Boehringer Ingelheim); Farm 4: Latest PRRSV outbreak <1 month prior to the first sampling event; Farm 5: Vaccinated with a modified live vaccine (Ingelvac PRRS® MLV, Boehringer Ingelheim). Samples were not collected on grey shaded sampling events.
Figure 1Porcine reproductive and respiratory syndrome virus (PRRSV) positive rate (%) in processing fluid and tonsil scraping specimens by stillborn fetus (%), mummified fetus (%), and pre-weaning pig death rates (%) in three breeding farms. aFarm 1. Latest PRRSV outbreak, ~6 months prior to the first sampling event. bFarm 2. Latest PRRSV outbreak, <1 month prior to the first sampling event. Vaccinated with a modified live vaccine (Fostera® PRRS, Zoetis Inc). cFarm 3. Vaccinated with a modified live vaccine (Ingelvac PRRS® MLV, Boehringer Ingelheim).
Figure 2Porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 phylogenetic consensus tree constructed using the maximum likelihood method with bootstrap resampling. Sequences from processing fluids (n = 34) of three breeding farms (Farm 1, 2, and 3), oral fluids (n = 7) of two growing farms (Farm 4 and 5), tonsil scraping (n = 12) of all recruited farms (Farms 1–5), 690 previously reported lineage anchors, and five PRRSV vaccine strains, were classified and compared. Sequences that are highly clustered are labeled only once due to the space limitation.
Porcine reproductive and respiratory syndrome virus (PRRSV)-positive proportion (%) in oral fluid and tonsil scraping specimens, average daily weight gain, and mortalities in two production batches of two growing pig farms (Farms 4 and 5).
|
| ||||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| 4 | 1 | 1 | 10.00 | 50.00 | 19.00 | 1.66 |
| 2 | 60.00 | 50.00 | 8.00 | 1.68 | ||
| 2 | 1 | 0.00 | 55.56 | 12.00 | 1.62 | |
| 2 | 25.00 | 33.33 | 7.00 | 1.84 | ||
| 3 | 1 | 11.11 | 66.67 | 6.00 | 1.68 | |
| 2 | 42.86 | 100.00 | 12.00 | 1.85 | ||
| 4 | 1 | 0.00 | 70.00 | 7.00 | 1.69 | |
| 2 | 57.14 | 83.33 | 10.00 | 1.77 | ||
| 5 | 1 | 1 | 57.14 | 66.67 | 4.09 | 1.90 |
| 2 | 57.14 | 14.29 | 4.68 | 1.87 | ||
| 2 | 1 | 10.00 | 53.85 | 4.36 | 1.82 | |
| 2 | 42.86 | 37.50 | 3.44 | 1.67 | ||
| 3 | 1 | 14.29 | 66.67 | 6.56 | 1.74 | |
| 2 | 16.67 | 25.00 | 3.81 | 1.83 | ||
| 4 | 1 | 0.00 | 87.50 | 5.95 | 1.73 | |
| 2 | 50.00 | 50.00 | 3.47 | 1.80 | ||
Farm 4. Latest PRRSV outbreak, <1 month prior to the first sampling event. Production batch 1 occurred April–September 2019 and production batch 2 October 2019–February 2020.
Farm 5. Vaccinated with a modified live vaccine (Ingelvac PRRS® MLV, Boehringer Ingelheim). Production batch 1 occurred April–October 2019 and production batch 2 November 2019–March 2020.